SG10201803618RA - Compounds for positron emission tomography - Google Patents

Compounds for positron emission tomography

Info

Publication number
SG10201803618RA
SG10201803618RA SG10201803618RA SG10201803618RA SG10201803618RA SG 10201803618R A SG10201803618R A SG 10201803618RA SG 10201803618R A SG10201803618R A SG 10201803618RA SG 10201803618R A SG10201803618R A SG 10201803618RA SG 10201803618R A SG10201803618R A SG 10201803618RA
Authority
SG
Singapore
Prior art keywords
compounds
positron emission
emission tomography
radical
radionuclide
Prior art date
Application number
SG10201803618RA
Inventor
Iontcho R Vlahov
Christopher P Leamon
Philip S Low
Garth L Parham
Qingshou Chen
Original Assignee
Endocyte Inc
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endocyte Inc, Purdue Research Foundation filed Critical Endocyte Inc
Publication of SG10201803618RA publication Critical patent/SG10201803618RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases

Abstract

COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY Described herein are compounds, compositions, and methods for diagnosing and/or monitoring pathogenic disease using positron emission tomography. Also described are conjugates of the formula B-L-P, wherein B is a radical of a targeting agent selected from vitamin receptor binding ligands (such as folate), PSMA binding ligands, or PSMA inhibitors; L is a divalent linker comprising aspartic acid, lysine, or arginine, and P is a radical of an imaging agent or radiotherapy agent, such as a radionuclide or radionuclide containing group, or a radical of a compound capable of binding a radionuclide, such as a metal chelating group. Figure 1A
SG10201803618RA 2013-11-14 2014-11-13 Compounds for positron emission tomography SG10201803618RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361904387P 2013-11-14 2013-11-14
US201361904400P 2013-11-14 2013-11-14
US201361909822P 2013-11-27 2013-11-27

Publications (1)

Publication Number Publication Date
SG10201803618RA true SG10201803618RA (en) 2018-06-28

Family

ID=53058011

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201803618RA SG10201803618RA (en) 2013-11-14 2014-11-13 Compounds for positron emission tomography

Country Status (14)

Country Link
US (3) US20160287731A1 (en)
EP (3) EP3533473A3 (en)
JP (5) JP6464166B2 (en)
KR (1) KR102457827B1 (en)
CN (2) CN105849568B (en)
AU (3) AU2014348601A1 (en)
BR (1) BR112016010927A2 (en)
CA (1) CA2930581A1 (en)
EA (1) EA035171B1 (en)
IL (2) IL245612A0 (en)
MX (2) MX2016006219A (en)
SG (1) SG10201803618RA (en)
TW (1) TWI657827B (en)
WO (1) WO2015073678A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010536790A (en) 2007-08-17 2010-12-02 パーデュー・リサーチ・ファウンデーション PSMA binding ligand-linker conjugate and method of use
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
BR112015011118B1 (en) 2012-11-15 2022-12-13 Endocyte, Inc CONJUGATE; PHARMACEUTICAL COMPOSITION; AND USE OF A CONJUGATE
TN2016000137A1 (en) 2013-10-18 2017-10-06 Deutsches Krebsforsch Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer.
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
HUE053064T2 (en) 2015-09-30 2021-06-28 Deutsches Krebsforsch 18f-tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancer
US10688200B2 (en) * 2015-12-31 2020-06-23 Five Eleven Pharma Inc. Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy
US10882871B2 (en) 2016-01-10 2021-01-05 British Columbia Cancer Agency Branch 18/19F-labelled compounds which target the prostate specific membrane antigen
WO2018026538A1 (en) * 2016-08-02 2018-02-08 ISI Life Sciences Inc. Novel scaffolds for intracellular compound delivery for the detection of cancer cells
WO2018026965A1 (en) 2016-08-02 2018-02-08 Isi Life Sciences, Inc. Compositions and methods for detecting cancer cells in a tissue sample
US10239891B2 (en) 2017-05-15 2019-03-26 Indicator Systems International, Inc. Compositions to detect remnant cancer cells
US11225496B2 (en) 2016-08-10 2022-01-18 Cancer Targeted Technology Llc Chelated PSMA inhibitors
WO2018098390A1 (en) * 2016-11-23 2018-05-31 Cancer Targeted Technology Llc Albumin-binding psma inhibitors
CN106632341A (en) * 2016-12-27 2017-05-10 天津阿尔塔科技有限公司 Method for synthesizing D-folic acid
US10753942B2 (en) 2017-05-15 2020-08-25 Indicator Systems International, Inc. Methods to detect remnant cancer cells
US20210276971A1 (en) * 2018-06-20 2021-09-09 The Research Foundation For The State University Of New York Triazamacrocycle-derived chelator compositions for coordination of imaging and therapy metal ions and methods of using same
CN108997170B (en) * 2018-08-07 2021-04-06 贾国苓 Polycarboxyl chelate easy to alkaline hydrolyze and preparation process thereof
WO2020108753A1 (en) * 2018-11-28 2020-06-04 ITM Isotopen Technologien München AG Novel tumor antigen binding agents and uses thereof
BR112021025810A2 (en) 2019-06-21 2022-05-10 Provincial Health Services Authority Radiolabeled compounds targeting prostate-specific membrane antigen
CN110627837A (en) * 2019-09-10 2019-12-31 齐鲁工业大学 Metal organic framework material for detecting carbon monoxide, preparation method and application
WO2022006007A1 (en) * 2020-06-29 2022-01-06 The General Hospital Corporation Methods for imaging bacterial infections
JP2024511235A (en) * 2021-03-20 2024-03-12 ザ リサーチ ファウンデイション フォー ザ ステイト ユニバーシティー オブ ニューヨーク Iron(III) macrocyclic complexes with mixed hydroxyl pendants as MRI contrast agents
WO2022219569A1 (en) * 2021-04-16 2022-10-20 Novartis Ag Folate receptor-targeted radiotherapeutic agents and their use
CN114028590B (en) * 2021-11-18 2022-09-06 北京大学 Granzyme B targeting complex, radiopharmaceutical, preparation methods and applications thereof
WO2023164161A2 (en) * 2022-02-24 2023-08-31 Purdue Research Foundation Conjugates, compositions, and methods for hydroxyapatite-targeted imaging and therapy

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795877A (en) 1996-12-31 1998-08-18 Guilford Pharmaceuticals Inc. Inhibitors of NAALADase enzyme activity
US5672592A (en) 1996-06-17 1997-09-30 Guilford Pharmaceuticals Inc. Certain phosphonomethyl-pentanedioic acid derivatives thereof
US5902817A (en) 1997-04-09 1999-05-11 Guilford Pharmaceuticals Inc. Certain sulfoxide and sulfone derivatives
US5863536A (en) 1996-12-31 1999-01-26 Guilford Pharmaceuticals Inc. Phosphoramidate derivatives
US5962521A (en) 1997-04-04 1999-10-05 Guilford Pharmaceuticals Inc. Hydroxamic acid derivatives
US6093382A (en) * 1998-05-16 2000-07-25 Bracco Research Usa Inc. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
AUPQ014799A0 (en) * 1999-05-04 1999-05-27 Access Pharmaceuticals Australia Pty Limited Amplification of folate-mediated targeting to tumor cells using polymers
US6692724B1 (en) * 1999-10-25 2004-02-17 Board Of Regents, The University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
CA2410906C (en) * 2000-06-02 2012-10-02 Board Of Regents, The University Of Texas System Ethylenedicysteine (ec)-drug conjugates
US7875612B2 (en) 2001-04-24 2011-01-25 Purdue Research Foundation Folate mimetics and folate-receptor binding conjugates thereof
CN101648028B (en) * 2002-05-06 2012-11-21 恩多塞特公司 Vitamin-targeted imaging agents
US7597876B2 (en) * 2007-01-11 2009-10-06 Immunomedics, Inc. Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
TWI367096B (en) 2003-01-27 2012-07-01 Endocyte Inc Vitamin-receptor binding drug delivery conjugates and pharmaceutical compositions
SI1592457T1 (en) * 2003-01-27 2012-12-31 Endocyte, Inc. Folate-vinblastine conjugate as medicament
US20050085417A1 (en) * 2003-10-16 2005-04-21 Thomas Jefferson University Compounds and methods for diagnostic imaging and therapy
WO2006012527A1 (en) 2004-07-23 2006-02-02 Endocyte, Inc. Bivalent linkers and conjugates thereof
JP5175723B2 (en) * 2005-07-05 2013-04-03 パーデュー・リサーチ・ファウンデーション Preparation of compositions for treating monocyte-mediated diseases
KR20130113543A (en) 2005-08-19 2013-10-15 엔도사이트, 인코포레이티드 Multi-drug ligand conjugates
WO2007042504A2 (en) * 2005-10-07 2007-04-19 Guerbet Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium
US9265746B2 (en) * 2006-05-31 2016-02-23 Merck & Cie Method for cell-specific targeting
US10925977B2 (en) * 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
EP2117604B1 (en) * 2007-01-11 2017-07-26 Immunomedics, Inc. Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
CA2677792C (en) * 2007-02-07 2015-04-14 Purdue Research Foundation Positron emission tomography imaging method
WO2008101231A2 (en) * 2007-02-16 2008-08-21 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
EP2136788B1 (en) * 2007-03-30 2011-10-26 Bind Biosciences, Inc. Cancer cell targeting using nanoparticles
RU2523909C2 (en) 2007-06-25 2014-07-27 Эндосайт, Инк. Conjugates, containing hydrophilic spacers of linkers
EP2921482B1 (en) * 2007-06-26 2018-09-05 The Johns Hopkins University Labeled inhibitors of prostate-specific membrane antigen (psma), biological evaluation, and use as imaging agents
JP2010536790A (en) * 2007-08-17 2010-12-02 パーデュー・リサーチ・ファウンデーション PSMA binding ligand-linker conjugate and method of use
WO2010019446A1 (en) * 2008-08-09 2010-02-18 University Of Iowa Research Foundation Nucleic acid aptamers
HUE059796T2 (en) * 2009-03-19 2022-12-28 Univ Johns Hopkins Psma-targeting compounds and uses thereof
WO2011106639A1 (en) * 2010-02-25 2011-09-01 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
US9951324B2 (en) * 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
CN101863924B (en) * 2010-05-17 2012-06-27 北京师范大学 Labeled 99mTc hydrazino-nicotinamide-dioxodecoyl-folic acid coordination compound and preparation method
CA2844151C (en) * 2011-08-05 2022-11-29 John W. Babich Radiolabeled prostate specific membrane antigen inhibitors
WO2013130776A1 (en) * 2012-02-29 2013-09-06 Purdue Research Foundation Folate receptor alpha binding ligands
EA201590622A1 (en) * 2012-10-16 2015-10-30 Эндосайт, Инк. CONJUGATES FOR DELIVERY OF MEDICINES CONTAINING NOT MEETING IN THE NATURE OF AMINO ACID AND METHODS OF APPLICATION
EP3036008A4 (en) * 2013-08-22 2017-04-05 Robert Doyle Compositions comprising vitamin b12 and intrinsic factor and methods of use thereof
CN103951668A (en) * 2014-04-25 2014-07-30 广州军区广州总医院 Positron isotope label of folic acid ramification and application thereof

Also Published As

Publication number Publication date
KR20160079887A (en) 2016-07-06
EP3069147A4 (en) 2017-10-11
IL261259B (en) 2020-07-30
AU2021200067A1 (en) 2021-03-18
JP2016540747A (en) 2016-12-28
MX2016006219A (en) 2016-10-28
EA035171B1 (en) 2020-05-08
AU2023202704A1 (en) 2023-05-18
US20220125958A1 (en) 2022-04-28
JP2019023232A (en) 2019-02-14
CA2930581A1 (en) 2015-05-21
CN108514646B (en) 2021-07-16
EP3777898A3 (en) 2021-04-21
IL245612A0 (en) 2016-06-30
EP3069147A1 (en) 2016-09-21
JP6464166B2 (en) 2019-02-06
CN105849568B (en) 2018-05-04
TW201609153A (en) 2016-03-16
US20160287731A1 (en) 2016-10-06
CN108514646A (en) 2018-09-11
NZ719939A (en) 2022-03-25
EA201690862A1 (en) 2016-12-30
MX2022014611A (en) 2023-01-11
IL261259A (en) 2018-10-31
BR112016010927A2 (en) 2017-08-08
EP3533473A2 (en) 2019-09-04
US20190275181A1 (en) 2019-09-12
AU2014348601A1 (en) 2016-05-26
WO2015073678A1 (en) 2015-05-21
KR102457827B1 (en) 2022-10-24
JP2020165975A (en) 2020-10-08
EP3777898A2 (en) 2021-02-17
JP7299285B2 (en) 2023-06-27
AU2021200067B2 (en) 2023-02-02
EP3533473A3 (en) 2019-12-18
TWI657827B (en) 2019-05-01
JP2023107988A (en) 2023-08-03
JP2022023172A (en) 2022-02-07
CN105849568A (en) 2016-08-10

Similar Documents

Publication Publication Date Title
MX2022014611A (en) Compounds for positron emission tomography.
MX2021008976A (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer.
MX2018008168A (en) Urea-based prostate specific membrane antigen (psma) inhibitors for imaging and therapy.
MX2022002401A (en) Radiopharmaceuticals, radioimaging agents, and uses thereof.
MX2015008993A (en) Triazine based radiopharmaceuticals and radioimaging agents.
PH12015501996A1 (en) Heterocyclic compounds and uses thereof
MX2017003886A (en) Radiopharmaceutical conjugate of a metabolite and an epr agent, for targeting tumour cells.
EA201890915A1 (en) CONJUGATES FOR DELIVERY OF MEDICINES AND METHODS OF TREATMENT OF DISEASES CAUSED BY CELLS EXPRESSING PSMA
WO2014152389A8 (en) Imaging agent for detection of diseased cells
MX343405B (en) Alpha-emitting complexes.
MX2015011830A (en) Methods of manufacture and synthesis of amino acid linking groups conjugated to compounds used for targeted imaging of tumors.
EA201491362A1 (en) ANESTHYZING COMPOUNDS AND METHODS OF THEIR APPLICATION
NZ739770A (en) 18f-tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancer
MX2018000239A (en) Hbed-bisphosphonates, radiometal conjugates thereof and their use as theranostic agents.
MX2013012793A (en) Radiolabeled amino acids for diagnostic imaging.
PH12020551471A1 (en) Psma-targeted radiopharmaceutical for diagnosing and treating prostate cancer
MX2019001053A (en) Chelated psma inhibitors.
JP2014508784A5 (en)
MX2016003725A (en) Compounds and their use for preparation of tau imaging agents and tau imaging formulations.
NZ758917A (en) Compounds for positron emission tomography
WO2013113801A3 (en) Chelating agents
MX2013012795A (en) Novel precursors of glutamate derivatives.
EA202090575A3 (en) CONNECTIONS FOR POSITRON EMISSION TOMOGRAPHY
NZ708849A (en) Radiopharmaceutical products for diagnosis and therapy of adrenal carcinoma
MX336322B (en) 99mtc-edda/hynic-ggc-aunp-mannose as a radiopharmaceutical for the detection of the sentinel node in breast cancer.